Purchase Order 36C24226P0214

The U.S. Department of Veterans Affairs, specifically Veterans Integrated Service Network 2, awarded a firm fixed-price purchase order to Pantherx Specialty, LLC (doing business as Pantherx Specialty Pharmacy) for emergency TARPEYO (budesonide) 4mg pharmaceutical supplies for the New York Harbor region. The contract, valued at $10,896.98, was awarded on December 9, 2025, with an ultimate completion date of January 8, 2026. No set-aside designation was applied to this procurement. Pantherx Specialty, a Pittsburgh, Pennsylvania-based specialty pharmacy and subsidiary of Centene Corporation, serves as the prime contractor and has established itself as a targeted provider of pharmaceutical solutions to the VA and other federal healthcare agencies.

This contract exemplifies the VA's use of specialized pharmaceutical suppliers to meet urgent medication needs within its integrated service networks. TARPEYO is a prescription medication used to treat certain kidney conditions, and the emergency nature of this procurement suggests time-sensitive medical requirements for veterans in the New York Harbor service area. Pantherx Specialty's consistent track record of supplying rare disease and specialized medications to VISN 2 and other federal healthcare entities positioned it as the awardee for this critical pharmaceutical need. The brief performance period reflects the urgent character of the procurement and the company's established capability to rapidly fulfill federal healthcare demands.